(Q53230213)

12 May 2018

title

Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. (English)

1 reference

12 May 2018

author name string

Feillet-Coudray C

1

1 reference

12 May 2018

Tourtauchaux R

2

1 reference

12 May 2018

Niculescu M

3

1 reference

12 May 2018

Rock E

4

1 reference

12 May 2018

Tauveron I

5

1 reference

12 May 2018

Alexandre-Gouabau MC

6

1 reference

12 May 2018

Rayssiguier Y

7

1 reference

12 May 2018

Jalenques I

8

1 reference

12 May 2018

Mazur A

9

1 reference

12 May 2018

publication date

1 August 1999

1 reference

12 May 2018

Free Radical Biology and Medicine

published in

1 reference

12 May 2018

volume

27

1 reference

12 May 2018

issue

3-4

1 reference

12 May 2018

page(s)

463-469

1 reference

12 May 2018

Aging and oxidative stress: modulation by dietary restriction

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

The generation and actions of isoprostanes.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

The isoprostanes: unique bioactive products of lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

The isoprostanes: a perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Increased oxidative stress in rat liver and pancreas during progression of streptozotocin-induced diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Total antioxidant status in plasma and body fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Homeostasis between lipid peroxidation and antioxidant enzyme activities in healthy human aging

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Oxidants, antioxidants, and the degenerative diseases of aging

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Alzheimer's disease. A glycation connection.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Abnormalities of Glucose Metabolism in Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

[Neuropathologic, immunologic and psychobiological aspects of Alzheimer's dementia]

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Oxidative stress hypothesis in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Lipid peroxidation and free radical scavengers in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Increased CSF F2-isoprostane concentration in probable AD.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type--place of the extracellular glutathione peroxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Free radicals and superoxide dismutase in blood of patients with Alzheimer's disease and vascular dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Determination of malonaldehyde in Alzheimer's disease: a comparative study of high-performance liquid chromatography and thiobarbituric acid test.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Oxidative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2899%2900096-9

7 January 2021

10.1016/S0891-5849(99)00096-9

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018